Li Dean Y (CIK 1837016) reported 15 SEC Form 4 insider transactions across 2 companies over the past 18 months (most recent 2026-07-02). Recent activity: Buy RXRX (3,747 shares), Buy RXRX (88,424 shares), Buy MRK (4,722 shares), Sell MRK (2,326 shares), Buy RXRX (3,268 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-02 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Director | Buy | 3,747 | $0 |
| 2026-06-22 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Director | Buy | 88,424 | $0 |
| 2026-05-01 | Merck & Co., Inc. (MRK) | Executive VP & President, MRL | Buy | 4,722 | $519,562 |
| 2026-05-01 | Merck & Co., Inc. (MRK) | Executive VP & President, MRL | Sell | 2,326 | $255,930 |
| 2026-04-02 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Director | Buy | 3,268 | $0 |
| 2026-02-10 | Merck & Co., Inc. (MRK) | Executive VP & President, MRL | Sell | 10,235 | $1.2M |
| 2026-02-06 | Merck & Co., Inc. (MRK) | Executive VP & President, MRL | Buy | 15,087 | $845,475 |
| 2026-02-06 | Merck & Co., Inc. (MRK) | Executive VP & President, MRL | Sell | 15,087 | $1.8M |
| 2026-01-28 | Merck & Co., Inc. (MRK) | Executive VP & President, MRL | Buy | 20,469 | $2.2M |
| 2026-01-06 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Director | Buy | 2,381 | $0 |
| 2025-10-03 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Director | Buy | 1,961 | $0 |
| 2025-07-03 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Director | Buy | 1,949 | $0 |
| 2025-06-23 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Director | Buy | 22,016 | $0 |
| 2025-04-03 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Director | Buy | 2,268 | $0 |
| 2025-01-29 | Merck & Co., Inc. (MRK) | Executive VP & President, MRL | Buy | 32,621 | $3.2M |
Source: SEC Form 4 filings · as of 2026-07-02